These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27518175)

  • 1. Evaluation Outcomes Associated with Alternative Dosing Strategies for Piperacillin/Tazobactam: A Systematic Review and Meta-Analysis.
    Yang H; Cui X; Ma Z; Liu L
    J Pharm Pharm Sci; 2016; 19(2):274-89. PubMed ID: 27518175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis.
    Yang H; Zhang C; Zhou Q; Wang Y; Chen L
    PLoS One; 2015; 10(1):e0116769. PubMed ID: 25575030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review.
    Mah GT; Mabasa VH; Chow I; Ensom MH
    Ann Pharmacother; 2012 Feb; 46(2):265-75. PubMed ID: 22274145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation?
    Attivi D; Gibaud S
    Ann Pharm Fr; 2014 May; 72(3):146-51. PubMed ID: 24780830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.
    Winstead EM; Ratliff PD; Hickson RP; Mueller JE; Judd WR
    Int J Clin Pharm; 2016 Oct; 38(5):1087-93. PubMed ID: 27333796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Economic Impact of Empirical Extended-Infusion Piperacillin-Tazobactam in a Community Medical Center.
    Brunetti L; Poustchi S; Cunningham D; Toscani M; Nguyen J; Lim J; Ding Y; Nahass RG
    Ann Pharmacother; 2015 Jul; 49(7):754-60. PubMed ID: 25855703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis.
    Falagas ME; Tansarli GS; Ikawa K; Vardakas KZ
    Clin Infect Dis; 2013 Jan; 56(2):272-82. PubMed ID: 23074314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and evidence for extended infusion of piperacillin-tazobactam.
    Kaufman SE; Donnell RW; Hickey WS
    Am J Health Syst Pharm; 2011 Aug; 68(16):1521-6. PubMed ID: 21817083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?
    Kim A; Sutherland CA; Kuti JL; Nicolau DP
    Pharmacotherapy; 2007 Nov; 27(11):1490-7. PubMed ID: 17963458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.
    Grant EM; Kuti JL; Nicolau DP; Nightingale C; Quintiliani R
    Pharmacotherapy; 2002 Apr; 22(4):471-83. PubMed ID: 11939682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance.
    Jansen JP; Kumar R; Carmeli Y
    Value Health; 2009; 12(2):234-44. PubMed ID: 20667059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections.
    Tice AD; Turpin RS; Hoey CT; Lipsky BA; Wu J; Abramson MA
    Am J Health Syst Pharm; 2007 May; 64(10):1080-6. PubMed ID: 17494908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients.
    Lee GC; Liou H; Yee R; Quan CF; Neldner K
    Clin Ther; 2012 Dec; 34(12):2297-300. PubMed ID: 23195962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
    Lodise TP; Lomaestro B; Drusano GL
    Clin Infect Dis; 2007 Feb; 44(3):357-63. PubMed ID: 17205441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
    Yost RJ; Cappelletty DM;
    Pharmacotherapy; 2011 Aug; 31(8):767-75. PubMed ID: 21923603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged Infusion Piperacillin-Tazobactam Decreases Mortality and Improves Outcomes in Severely Ill Patients: Results of a Systematic Review and Meta-Analysis.
    Rhodes NJ; Liu J; O'Donnell JN; Dulhunty JM; Abdul-Aziz MH; Berko PY; Nadler B; Lipman J; Roberts JA
    Crit Care Med; 2018 Feb; 46(2):236-243. PubMed ID: 29116995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials.
    An MM; Zou Z; Shen H; Zhang JD; Chen ML; Liu P; Wang R; Jiang YY
    BMC Infect Dis; 2009 Dec; 9():193. PubMed ID: 19951447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical and economic benefits of administering piperacillin-tazobactam by continuous infusion.
    Kotapati S; Kuti JL; Geissler EC; Nightingale CH; Nicolau DP
    Intensive Crit Care Nurs; 2005 Apr; 21(2):87-93. PubMed ID: 15778072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.
    Cotrina-Luque J; Gil-Navarro MV; Acosta-García H; Alfaro-Lara ER; Luque-Márquez R; Beltrán-García M; Bautista-Paloma FJ
    Int J Clin Pharm; 2016 Feb; 38(1):70-9. PubMed ID: 26474861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.
    Bao H; Lv Y; Wang D; Xue J; Yan Z
    Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):459-466. PubMed ID: 27796647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.